[Evaluation of clinical evidence for dalbavancin]

Gram-positive infections are currently a therapeutic challenge because of the emergence of strains resistant to first-line antibiotics. Consequently, in the last few years, new antibiotics have been developed with activity against multiresistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and strains with intermediate sensitivity to vancomycin. Among the new antibiotics approved for the treatment of these microorganisms, dalbavancin is a semisynthetic lipoglycopeptide derived from teicoplanin, but has a superior efficacy profile to the latter. Studies published to date have confirmed the efficacy, safety and tolerability of dalbavancin in the treatment of skin and soft tissue infections caused by Gram-positive microorganisms sensitive to this drug and position it as a therapeutic option in Gram-positive catheter-related sepsis. Dalbavancin has an excellent safety profile and pharmacokinetics that allow its intravenous administration in a single weekly dose, making it a therapeutic option for outpatient use. Dalbavancin could also be an attractive alternative for patients requiring prolonged antibiotic therapy, with the aim of avoiding the need for a permanent intravenous line and its associated risks, such as infection and/or septic thrombophlebitis.